These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11006039)

  • 21. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.
    Mouratidou D; Gennatas C; Michalaki V; Papadimitriou A; Andreadis CH; Sykiotis C; Tsavaris N
    Anticancer Res; 2007; 27(1B):681-5. PubMed ID: 17348460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma.
    Chin SN; Pinto V; Rosen B; Oza A; Dodge J; Murphy J; Mackay H
    Gynecol Oncol; 2009 Mar; 112(3):450-4. PubMed ID: 19135709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
    Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carboplatin, cisplatin and paclitaxel in the treatment of patients with epithelial ovarian cancer.
    De Placido S; Tramontana S; Ferrari E; De Matteis A; Lauria R; Perrone F; Bianco AR; Gallo C; Ricchi P; De Placido G; Pignata S;
    Anticancer Res; 2000; 20(5C):4023-9. PubMed ID: 11268496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
    Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
    J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-13-S2-16. PubMed ID: 9045329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
    Gemignani ML; Hensley ML; Cohen R; Venkatraman E; Saigo PE; Barakat RR
    Gynecol Oncol; 2001 Jan; 80(1):16-20. PubMed ID: 11136563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
    Gronlund B; Høgdall C; Hansen HH; Engelholm SA
    Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Phase II study of paclitaxel and cisplatin for advanced squamous-cell carcinoma of esophagus].
    Huang J; Cai RG; Meng PJ; Zhang MJ; Cui CX; Yang L; Chu DT; Sun Y; Wang JW
    Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):753-5. PubMed ID: 15733398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
    Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secondary surgical cytoreduction for advanced ovarian carcinoma.
    Rose PG; Nerenstone S; Brady MF; Clarke-Pearson D; Olt G; Rubin SC; Moore DH; Small JM;
    N Engl J Med; 2004 Dec; 351(24):2489-97. PubMed ID: 15590951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Aravantinos G; Fountzilas G; Bamias A; Grimani I; Rizos S; Kalofonos HP; Skarlos DV; Economopoulos T; Kosmidis PA; Stathopoulos GP; Briasoulis E; Pectasides D; Samantas E; Timotheadou E; Papadimitriou C; Papanikolaou A; Onyenadum A; Papakostas P; Bafaloukos D; Dimopoulos MA;
    Eur J Cancer; 2008 Oct; 44(15):2169-77. PubMed ID: 18691879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF; Liu FY; Chen FJ; Feng YL
    Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.
    Stathopoulos GP; Malamos NA; Aravantinos G; Rigatos S; Christodoulou Ch; Stathopoulos J; Skarlos D
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):123-8. PubMed ID: 17111119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.